Javier Szwarcberg
Chief Executive Officer at SPRUCE BIOSCIENCES, INC.
Net worth: 84 354 $ as of 2024-03-30
Profile
Javier Szwarcberg is currently the Chief Executive Officer & Director at Spruce Biosciences, Inc. Prior to this, he worked as the VP, Head-Product & Portfolio Management at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Plc from 2016 to 2017.
He holds a doctorate degree from Universidad de Buenos Aires and a graduate degree from Harvard T.H.
Chan School of Public Health.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC.
0.26% | 2024-03-13 | 107,321 ( 0.26% ) | 84 354 $ | 2024-03-30 |
Javier Szwarcberg active positions
| Companies | Position | Start |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Chief Executive Officer | 2022-01-02 |
Former positions of Javier Szwarcberg
| Companies | Position | End |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 2021-12-31 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 2020-01-31 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2017-09-30 |
Training of Javier Szwarcberg
| Universidad de Buenos Aires | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Javier Szwarcberg
